ArticleOpen forum infectious diseases2025
Budget Impact of Adopting Nirmatrelvir-Ritonavir for Treating COVID-19 in a Large Integrated Healthcare System.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Understanding the budget impact of prescribing nirmatrelvir-ritonavir (NR) for COVID-19 can inform procurement and allocation strategies in large healthcare systems. Methods: We assessed the budget impact of providing NR in the Veterans Health Administration (VHA) for all treatment-eligible Veterans (laboratory-confirmed COVID-19 illness from April 2022 through March 2023) and by clinical subgroups, including predicted hospitalization/death risk quartile. We used decision tree models that included 30-day emergency department (ED) visits, hospitalizations, and death to assess the budget impact of NR. Transition probabilities were derived from a target trial emulation of NR effectiveness in the same population. We priced NR at $1031/course and used cost accounting records to estimate ED ($1420), hospitalization ($22 419), and hospitalization with ICU ($59 918) costs. Results: Among 138 261 treatment-eligible Veterans, 18% ( Conclusions: NR may reduce 30-day COVID-19 healthcare utilization costs, but the high cost of purchasing NR is likely to exceed those savings. Price reductions are necessary for NR to be a financially viable treatment for healthcare systems. Risk-informed allocation strategies can help maximize treatment benefits and minimize budget increases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.